
March 20, 2020
Alexander co-authors study in Lancet Oncology
This was the first peer-reviewed study of venetoclax in a pediatric population, and first study using the drug with intensive acute myeloid leukemia chemotherapy.
March 20, 2020
This was the first peer-reviewed study of venetoclax in a pediatric population, and first study using the drug with intensive acute myeloid leukemia chemotherapy.
January 14, 2020
An early-stage clinical study investigating a method of boosting the body’s defenses against two blood cancers found the drug pomalidomide could be safely added to conventional treatments, and help improve immune function. University of North Carolina Lineberger Comprehensive Cancer Center researcher Joshua Zeidner, MD, assistant professor in the UNC School of Medicine Division of Hematology/Oncology, …
September 30, 2019
At the 15th annual Roy Williams Fast Break against Cancer, Chad Holbrook offered a compelling reason why to support UNC Lineberger and its mission: the health of his son Reece, who is a cancer survivor and a top prospect high school baseball player.
September 3, 2019
The Leukemia & Lymphoma Society has awarded a $971,484 Screen to Lead grant to University of North Carolina Lineberger Comprehensive Cancer Center researchers to launch an investigation of new drug compounds that would block enzymes that can become hyperactive in blood cancer cells when mutated. UNC Lineberger’s John Sondek, PhD, a professor in the UNC …
August 30, 2019
July 12, 2019
Jack Goldstein, 14, and his family had to make sacrifices when Jack was diagnosed with leukemia. But when Jack put his schoolwork and baseball training on hold, his family and friends were there to support him.
May 10, 2019
After a two-year journey, Lorelei rings the bell at the UNC Pediatric Hematology Oncology clinic, signaling an end to her treatments for acute lymphoblastic leukemia.
January 10, 2019
Decorated military veteran MG Autry says service to others is central to his life. Even when he is facing his own health challenges, he would have it no other way.
December 21, 2018
UNC Lineberger’s Joshua Zeidner, MD, reported preliminary data at the 60th American Society of Hematology Annual Meeting from a phase II clinical trial for administering a high-dose of the chemotherapy treatment cytarabine followed by an immune checkpoint inhibitor, pembrolizumab, in patients with acute myeloid leukemia that had relapsed or no longer responded to other treatment.
December 20, 2018